Changeflow GovPing Pharma & Drug Safety Mannanase variants and polynucleotides encoding...
Routine Notice Added Final

Mannanase variants and polynucleotides encoding same

Favicon for changeflow.com ChangeBridge: Patent Grants - Biotech (C12N)
Published
Detected
Email

Summary

USPTO granted patent US12595472B2 to BASF SE for mannanase enzyme variants at least 75% identical to SEQ ID NO: 2 or 3, including encoding polynucleotides, expression constructs, and host cells. The patent, filed February 12, 2021, contains 14 claims and is classified under CPC C12N 9/2488.

What changed

USPTO issued patent grant US12595472B2 to BASF SE covering mannanase enzyme variants with at least 75% sequence identity to specified sequences, along with related polynucleotides, expression constructs, and host cells containing these elements. The patent names seven inventors and grants exclusive rights to the assignee.

This patent grant establishes intellectual property rights that may restrict others from making, using, or commercializing similar mannanase variants without BASF SE's permission. Competitors developing enzyme products in related applications should review the patent claims for potential infringement risks or consider licensing opportunities.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Mannanase variants

Grant US12595472B2 Kind: B2 Apr 07, 2026

Assignee

BASF SE

Inventors

Katie Kline, Amanda Rae Logue, Asfia Qureshi, Cindy Hoang, Jesper Nielsen, Mark Miller, James Garrett Bonner

Abstract

A mannanase at least 75% identical to SEQ ID NO: 2 or SEQ ID NO: 3, a polynucleotide encoding the mannanase, an expression construct comprising the polynucleotide, and a host cell comprising the polynucleotide or the expression construct.

CPC Classifications

C12N 9/2488

Filing Date

2021-02-12

Application No.

17799049

Claims

14

View original document →

Get daily alerts for ChangeBridge: Patent Grants - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12595472B2

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent licensing Enzyme manufacturing Biotech research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Biotechnology

Get alerts for this source

We'll email you when ChangeBridge: Patent Grants - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.